Cantor Fitzgerald Downgrades Collegium Pharmaceutical to Neutral, Lowers Price Target to $22
Cantor Fitzgerald analyst Brandon Folkes downgrades Collegium Pharmaceutical (NASDAQ:COLL) from Overweight to Neutral and lowers the price target from $30 to $22.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $32
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $34 to $32.
HC Wainwright & Co. Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $28
HC Wainwright & Co. analyst Oren Livnat maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $33 to $28.
Collegium Pharmaceutical Q2 EPS $1.79 Up From $0.23 YoY, Sales $82.94M Miss $84.77M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.79 per share. This is a 678.26 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.